Perfil
Mr. Louis J.
Arcudi is a Chief Financial Officer at Sensorion SA and a Co-President & Secretary at Millendo Therapeutics US, Inc. Mr. Arcudi was previously employed as a President, Chief Executive Officer & Director by Millendo Therapeutics, Inc., a CFO, Treasurer & Chief Accounting Officer by Idera Pharmaceuticals, Inc., a Treasurer, VP-Administration & Finance by Peptimmune, Inc., a Senior Director-Finance Business Planning by Genzyme Corp., a Senior Director-Finance & Administration by Genzyme Molecular Oncology, a Chief Financial Officer by Amolyt Pharma SAS, and a Controller by Cognex Corp.
He received his undergraduate degree from Southern New Hampshire University and an MBA from Bryant University.
Cargos activos de Louis Arcudi
| Empresas | Cargo | Inicio |
|---|---|---|
| SENSORION | Director Financiero/CFO | 07/10/2026 |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | Presidente | - |
Antiguos cargos conocidos de Louis Arcudi.
| Empresas | Cargo | Fin |
|---|---|---|
| MILLENDO THERAPEUTICS | Director Ejecutivo | 25/06/2021 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Director Financiero/CFO | 31/10/2018 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceutical products | Director Financiero/CFO | 01/12/2007 |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Develops novel cancer therapeutics and diagnostics | Director Financiero/CFO | 01/01/2003 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Director Financiero/CFO | 01/01/2003 |
Formación de Louis Arcudi.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 11 |
|---|---|
Cognex Corp.
Cognex Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and markets machine vision computer systems | Electronic Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceutical products | Health Technology |
Southern New Hampshire University
Southern New Hampshire University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Develops novel cancer therapeutics and diagnostics | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sensorion SA
Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Miscellaneous Commercial ServicesCommercial Services Engages in research and development in physical & natural sciences | Commercial Services |
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Bolsa de valores
- Insiders
- Louis Arcudi
















